South African guideline for the use of chronic opioid therapy for chronic non-cancer pain

Raff, M.; Crosier, J.; Eppel, S.; Meyer, Helgard Pieter; Sarembock, B.; Webb, D.

dc.contributor.author	Raff, M.
dc.contributor.author	Crosier, J.
dc.contributor.author	Eppel, S.
dc.contributor.author	Meyer, Helgard Pieter
dc.contributor.author	Sarembock, B.
dc.contributor.author	Webb, D.
dc.date.accessioned	2014-03-07T09:40:37Z
dc.date.available	2014-03-07T09:40:37Z
dc.date.issued	2014-01
dc.description.abstract	Chronic pain may have a significant impact on health-related quality of life and can be difficult to manage. In carefully selected patients, and as part of a comprehensive pain management strategy, opioid analgesia may help to achieve long-term pain control with a manageable side-effect profile and a low risk of serious adverse effects. However, appropriate evaluation, including biopsychosocial screening and risk screening is essential before initiating an opioid and during continued therapy. This guideline aims to assist practitioners in screening and selecting appropriate patients with chronic non-cancer pain to initiate, monitor and continue pain management with opioid therapy.	en_US
dc.description.librarian	am2014	en_US
dc.description.sponsorship	The development of this guideline was supported by an unrestricted grant from Mundipharma who did not participate in the development or writing of the guideline. Dr M Raff has received honoraria for consultancies and non-restricted research grants from Mundipharma, Pfizer, Janssen Pharmaceutica, AstraZeneca, MSD, Eli Lilly, Aspen and Abbott Laboratories. Drs J Crosier and S Eppel have received honoraria from Mundipharma. Prof. H Meyer has received honoraria for consultancies and non-restricted research grants from Janssen Pharmaceutica, Eli Lilly, MSD and Mundipharma. Dr B Sarembock has received honoraria for consultancies and non-restricted research grants from MSD, AstraZeneca, Pfizer and Mundipharma. Dr D Webb has received professional fees for services to Abbott Laboratories, Adcock Ingram, Alcon Laboratories, AstraZeneca, Eli Lilly, Janssen Pharmaceutica, Mundipharma, Novartis, and Reckitt Beckiser Pharmaceuticals.	en_US
dc.description.uri	http://www.samj.org.za	en_US
dc.identifier.citation	Raff, M, Crosier, J, Eppel, S, Meyer, H, Sarembock, B & Webb, D 2014, 'South African guideline for the use of chronic opioid therapy for chronic non-cancer pain', South African Medical Journal, vol. 104, no. 1, pp. 79-89.	en_US
dc.identifier.issn	0256-9574 (print)
dc.identifier.issn	2078-5135 (online)
dc.identifier.other	10.7196/SAMJ.7316
dc.identifier.uri	http://hdl.handle.net/2263/37093
dc.language.iso	en	en_US
dc.publisher	Health and Medical Publishing Group	en_US
dc.rights	Health and Medical Publishing Group	en_US
dc.subject	Chronic	en_US
dc.subject	Opioid therapy	en_US
dc.subject	Quality of life	en_US
dc.subject	Cancer	en_US
dc.subject	Patients	en_US
dc.title	South African guideline for the use of chronic opioid therapy for chronic non-cancer pain	en_US
dc.type	Article	en_US